Medicare Enrolled
Dr. Ajay Sehgal, MD
Hematology & Oncology · Corpus Christi, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sehgal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sehgal? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sehgal
Dr. Ajay Sehgal is a hematology & oncology in Corpus Christi, TX, with 19 years in practice. Based on federal Medicare data, Dr. Sehgal performed 101,610 Medicare services across 1,404 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sehgal received a total of $14,123 from 69 pharmaceutical and/or device companies across 641 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sehgal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 7% volume in TX$ $14,123 industry payments
Medicare Practice Summary
Medicare Utilization ↗101,610
Medicare services
Top 7% in TX for hematology & oncology
1,404
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,348 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 48,720 | $24 | $45 |
| Iron infusion (Feraheme) | 18,870 | $0 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 10,948 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 7,920 | $18 | $30 |
| Dexamethasone injection (steroid) | 7,839 | $0 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 1,780 | $21 | $60 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 888 | $107 | $400 |
| Administration of chemotherapy into vein, 1 hour or less | 852 | $95 | $275 |
| Injection, diphenhydramine hcl, up to 50 mg | 663 | $1 | $2 |
| Drug injection, under skin or into muscle | 452 | $10 | $40 |
| Office visit, established patient (30-39 min) | 355 | $91 | $160 |
| Injection, carboplatin, 50 mg | 347 | $2 | $5 |
| Administration of additional new drug or substance into vein, 1 hour or less | 302 | $47 | $135 |
| Unclassified drugs | 276 | $0 | $15 |
| Administration of chemotherapy into vein, each additional hour | 232 | $20 | $60 |
| Office visit, established patient, complex (40-54 min) | 151 | $127 | $300 |
| Telephone medical discussion with physician, 21-30 minutes | 118 | $87 | $200 |
| Infusion into a vein for hydration, each additional hour | 116 | $10 | $30 |
| New patient office visit, complex (60-74 min) | 109 | $154 | $400 |
| Injection, zoledronic acid, 1 mg | 104 | $7 | $20 |
| Office visit, established patient (20-29 min) | 90 | $60 | $150 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 88 | $53 | $150 |
| Hospital follow-up visit, high complexity | 75 | $91 | $190 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 74 | $17 | $50 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 64 | $46 | $140 |
| Irrigation of implanted venous access drug delivery device | 55 | $17 | $50 |
| Administration of prolonged chemotherapy into vein | 48 | $88 | $300 |
| Administration of additional new drug or substance into vein using push technique | 42 | $42 | $85 |
| Injection of additional new drug or substance into vein | 18 | $12 | $50 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $64 | $160 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
20.5% high complexity
77.9% medium
1.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,123
Total received (2018-2024)
Avg $2,018/year across 7 years
Top 25% in TX for hematology & oncology
69
Companies
641
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,222 (86.5%)
Other
Charitable contributions, space rental, and other categories
$1,415 (10.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$336 (2.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$150 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,285
2023$2,719
2022$2,487
2021$1,872
2020$580
2019$1,044
2018$1,137
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,488
E.R. Squibb & Sons, L.L.C.
$1,505
PFIZER INC.
$813
AstraZeneca Pharmaceuticals LP
$766
Merck Sharp & Dohme LLC
$658
Janssen Biotech, Inc.
$572
Celgene Corporation
$406
Lilly USA, LLC
$365
Karyopharm Therapeutics Inc.
$364
Gilead Sciences, Inc.
$288
Incyte Corporation
$286
Takeda Pharmaceuticals U.S.A., Inc.
$271
Genentech USA, Inc.
$257
Daiichi Sankyo Inc.
$237
Kite Pharma, Inc.
$231
GlaxoSmithKline, LLC.
$227
Eisai Inc.
$221
Astellas Pharma US Inc
$220
ADC Therapeutics America, Inc.
$210
Seagen Inc.
$204
GENZYME CORPORATION
$201
AVEO Pharmaceuticals, Inc.
$180
Stryker Corporation
$170
TAIHO ONCOLOGY, INC.
$168
Regeneron Healthcare Solutions, Inc.
$164
Merck Sharp & Dohme Corporation
$158
COMSORT, Inc
$150
BeiGene USA, Inc.
$138
Exelixis Inc.
$134
ARRAY BIOPHARMA INC
$133
Ipsen Biopharmaceuticals, Inc
$131
Melinta Therapeutics, LLC
$130
Mirati Therapeutics, Inc.
$119
Puma Biotechnology, Inc.
$117
Janssen Scientific Affairs, LLC
$105
Nevro Corp.
$83
MorphoSys, US Inc.
$81
Pharmacyclics LLC, An AbbVie Company
$76
ABBVIE INC.
$72
SOBI, INC
$70
Boehringer Ingelheim Pharmaceuticals, Inc.
$64
Pharmacyclics LLC, an AbbVie Company
$58
AbbVie, Inc.
$52
Clovis Oncology, Inc.
$52
EISAI INC.
$52
EMD Serono, Inc.
$48
Dova Pharmaceuticals
$44
Coherus Biosciences Inc.
$38
Myovant Sciences Inc.
$38
AbbVie Inc.
$37
Sobi, Inc
$35
PUMA BIOTECHNOLOGY, INC.
$31
Stemline Therapeutics Inc.
$31
Bayer Healthcare Pharmaceuticals Inc.
$30
Alexion Pharmaceuticals, Inc.
$30
Sandoz Inc.
$29
SECURA BIO, INC.
$29
Epizyme, Inc.,
$28
Organon Llc
$28
Mylan Institutional Inc.
$28
TESARO, Inc.
$23
Janssen Pharmaceuticals, Inc
$22
Tempus AI, Inc
$20
ImmunoGen, Inc.
$20
Bayer HealthCare Pharmaceuticals Inc.
$19
Rigel Pharmaceuticals, Inc.
$19
Blueprint Medicines Corporation
$18
Taiho Oncology, Inc.
$18
SpringWorks Therapeutics, Inc.
$15
Top 3 companies account for 34.0% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · Abraxane · Alecensa · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Elahere · Enhertu · Erleada · FOTIVDA · FRUZAQLA · Fabhalta · GAVRETO · GILOTRIF · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kimyrsa · LIBTAYO · LONSURF · LORBRENA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nubeqa · OGIVRI · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Omnia · Onivyde · Orserdu · PADCEV · PIQRAY · PROMACTA · Padcev · Phesgo · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SPY-PHI SYSTEM · SUTENT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tecentriq Hybreza · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · XALKORI · XPOVIO · XTANDI · Xospata · Xtandi · Yescarta · ZARXIO · ZEJULA · ZIEXTENZO · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $14 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
4
Per 100K population
1.1
County median income
$66,021
Nearest hospital
CORPUS CHRISTI MEDICAL CENTER,THE
3.0 mi
3.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sehgal is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sehgal experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Sehgal performed 48,720 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sehgal receive payments from pharmaceutical companies?
Yes. Dr. Sehgal received a total of $14,123 from 69 companies across 641 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sehgal's costs compare to other hematology & oncologys in Corpus Christi?
Dr. Sehgal's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sehgal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Corpus Christi
Browse hematology & oncologys in Corpus Christi ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology